Cargando…

The role of erlotinib and the Optune device in a patient with an epidermal growth factor receptor viii amplified glioblastoma

The standard treatment for patients diagnosed with glioblastoma is surgical resection of tumor followed by high dose radiation and chemotherapy with temozolomide. For patients who experience allergic reactions to temozolomide despite desensitization protocols, alternative therapies must be considere...

Descripción completa

Detalles Bibliográficos
Autores principales: Doyle, Sean P, Gurbani, Saumya S, Ross, Alexandra S, Rosen, Havi, Barrett, Charlice Dunn, Olson, Jeffrey J, Shim, Hyunsuk, Shu, Hui-Kuo, Sengupta, Soma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6217712/
https://www.ncbi.nlm.nih.gov/pubmed/30410775
http://dx.doi.org/10.1093/omcr/omy095
_version_ 1783368346033455104
author Doyle, Sean P
Gurbani, Saumya S
Ross, Alexandra S
Rosen, Havi
Barrett, Charlice Dunn
Olson, Jeffrey J
Shim, Hyunsuk
Shu, Hui-Kuo
Sengupta, Soma
author_facet Doyle, Sean P
Gurbani, Saumya S
Ross, Alexandra S
Rosen, Havi
Barrett, Charlice Dunn
Olson, Jeffrey J
Shim, Hyunsuk
Shu, Hui-Kuo
Sengupta, Soma
author_sort Doyle, Sean P
collection PubMed
description The standard treatment for patients diagnosed with glioblastoma is surgical resection of tumor followed by high dose radiation and chemotherapy with temozolomide. For patients who experience allergic reactions to temozolomide despite desensitization protocols, alternative therapies must be considered. In this report, we present such a patient who then received treatment with an epidermal growth factor receptor inhibitor, erlotinib, concurrent with a tumor-treating field device, Optune. Through this combination of a targeted molecular therapy and the Optune device, the patient has been able to achieve stable disease 9 months after completing radiation.
format Online
Article
Text
id pubmed-6217712
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-62177122018-11-08 The role of erlotinib and the Optune device in a patient with an epidermal growth factor receptor viii amplified glioblastoma Doyle, Sean P Gurbani, Saumya S Ross, Alexandra S Rosen, Havi Barrett, Charlice Dunn Olson, Jeffrey J Shim, Hyunsuk Shu, Hui-Kuo Sengupta, Soma Oxf Med Case Reports Case Report The standard treatment for patients diagnosed with glioblastoma is surgical resection of tumor followed by high dose radiation and chemotherapy with temozolomide. For patients who experience allergic reactions to temozolomide despite desensitization protocols, alternative therapies must be considered. In this report, we present such a patient who then received treatment with an epidermal growth factor receptor inhibitor, erlotinib, concurrent with a tumor-treating field device, Optune. Through this combination of a targeted molecular therapy and the Optune device, the patient has been able to achieve stable disease 9 months after completing radiation. Oxford University Press 2018-11-05 /pmc/articles/PMC6217712/ /pubmed/30410775 http://dx.doi.org/10.1093/omcr/omy095 Text en © The Author(s) 2018. Published by Oxford University Press. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Doyle, Sean P
Gurbani, Saumya S
Ross, Alexandra S
Rosen, Havi
Barrett, Charlice Dunn
Olson, Jeffrey J
Shim, Hyunsuk
Shu, Hui-Kuo
Sengupta, Soma
The role of erlotinib and the Optune device in a patient with an epidermal growth factor receptor viii amplified glioblastoma
title The role of erlotinib and the Optune device in a patient with an epidermal growth factor receptor viii amplified glioblastoma
title_full The role of erlotinib and the Optune device in a patient with an epidermal growth factor receptor viii amplified glioblastoma
title_fullStr The role of erlotinib and the Optune device in a patient with an epidermal growth factor receptor viii amplified glioblastoma
title_full_unstemmed The role of erlotinib and the Optune device in a patient with an epidermal growth factor receptor viii amplified glioblastoma
title_short The role of erlotinib and the Optune device in a patient with an epidermal growth factor receptor viii amplified glioblastoma
title_sort role of erlotinib and the optune device in a patient with an epidermal growth factor receptor viii amplified glioblastoma
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6217712/
https://www.ncbi.nlm.nih.gov/pubmed/30410775
http://dx.doi.org/10.1093/omcr/omy095
work_keys_str_mv AT doyleseanp theroleoferlotinibandtheoptunedeviceinapatientwithanepidermalgrowthfactorreceptorviiiamplifiedglioblastoma
AT gurbanisaumyas theroleoferlotinibandtheoptunedeviceinapatientwithanepidermalgrowthfactorreceptorviiiamplifiedglioblastoma
AT rossalexandras theroleoferlotinibandtheoptunedeviceinapatientwithanepidermalgrowthfactorreceptorviiiamplifiedglioblastoma
AT rosenhavi theroleoferlotinibandtheoptunedeviceinapatientwithanepidermalgrowthfactorreceptorviiiamplifiedglioblastoma
AT barrettcharlicedunn theroleoferlotinibandtheoptunedeviceinapatientwithanepidermalgrowthfactorreceptorviiiamplifiedglioblastoma
AT olsonjeffreyj theroleoferlotinibandtheoptunedeviceinapatientwithanepidermalgrowthfactorreceptorviiiamplifiedglioblastoma
AT shimhyunsuk theroleoferlotinibandtheoptunedeviceinapatientwithanepidermalgrowthfactorreceptorviiiamplifiedglioblastoma
AT shuhuikuo theroleoferlotinibandtheoptunedeviceinapatientwithanepidermalgrowthfactorreceptorviiiamplifiedglioblastoma
AT senguptasoma theroleoferlotinibandtheoptunedeviceinapatientwithanepidermalgrowthfactorreceptorviiiamplifiedglioblastoma
AT doyleseanp roleoferlotinibandtheoptunedeviceinapatientwithanepidermalgrowthfactorreceptorviiiamplifiedglioblastoma
AT gurbanisaumyas roleoferlotinibandtheoptunedeviceinapatientwithanepidermalgrowthfactorreceptorviiiamplifiedglioblastoma
AT rossalexandras roleoferlotinibandtheoptunedeviceinapatientwithanepidermalgrowthfactorreceptorviiiamplifiedglioblastoma
AT rosenhavi roleoferlotinibandtheoptunedeviceinapatientwithanepidermalgrowthfactorreceptorviiiamplifiedglioblastoma
AT barrettcharlicedunn roleoferlotinibandtheoptunedeviceinapatientwithanepidermalgrowthfactorreceptorviiiamplifiedglioblastoma
AT olsonjeffreyj roleoferlotinibandtheoptunedeviceinapatientwithanepidermalgrowthfactorreceptorviiiamplifiedglioblastoma
AT shimhyunsuk roleoferlotinibandtheoptunedeviceinapatientwithanepidermalgrowthfactorreceptorviiiamplifiedglioblastoma
AT shuhuikuo roleoferlotinibandtheoptunedeviceinapatientwithanepidermalgrowthfactorreceptorviiiamplifiedglioblastoma
AT senguptasoma roleoferlotinibandtheoptunedeviceinapatientwithanepidermalgrowthfactorreceptorviiiamplifiedglioblastoma